Citing its potential cancer risk, the FDA has requested the removal of Arena Pharmaceuticals’ (ARNA -1.1%) Belviq (lorcaserin) from the U.S. market.
Licensee Eisai (OTCPK:ESALY N/A) has submitted a filing to voluntarily withdraw the drug.
Update: Arena sold the rights to Eisai in 2017 for $23M in cash and over $80M in cost relief.
https://seekingalpha.com/news/3541893-fda-requests-removal-of-weight-loss-med-belviq
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.